Literature DB >> 10215677

Clearance of human brain natriuretic peptide in rabbits; effect of the kidney, the natriuretic peptide clearance receptor, and peptidase activity.

R Almirez1, A A Protter.   

Abstract

Although the synthetic version of the cardiac peptide human brain natriuretic peptide (hBNP) has demonstrated beneficial cardiovascular effects in clinical studies, little is known about mechanisms governing its elimination from the blood. This study measured the role of the kidney, the natriuretic peptide clearance (NP-C) receptor, and peptidase digestion on the elimination of synthetic hBNP from the plasma compartment of rabbits. The estimated plasma steady state resulting from a continuous i.v. infusion was achieved within 50 min and was related in a linear manner with the infusion rate of the drug. Complete restriction of kidney blood flow by bilateral suture-ligation of the renal arteries compared with sham-treated animals reduced the clearance of hBNP by approximately half (24 +/- 9 ml/min versus 47 +/- 14 ml/min, respectively, p <. 007). Pharmacological blockade of the NP-C receptor with a clearance receptor-specific analog of atrial natriuretic peptide increased in a statistically significant and dose-related manner the plasma steady-state level of hBNP during continuous i.v. infusion of hBNP (maximum effect of 1.9 +/- 0.3-fold, p <.01). The peptidase inhibitor phosphoramidon increased in a dose-related manner the plasma steady-state level of hBNP 1.7 +/- 0.4-fold during continuous i.v. infusion of hBNP in rabbits. These data suggest that the kidney, the NP-C receptor, and peptidases are all important in the elimination of hBNP from the plasma compartment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10215677

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Marked decrease in BNP levels in 2 related patients with reversible dilated cardiomyopathy.

Authors:  Ikuo Misumi; Kazuteru Fujimoto; Yuji Miyao; Mitsuhiro Matsumoto; Taku Rokutanda; Yousuke Hanaoka; Koichi Kaikita; Megumi Yamamuro; Seigo Sugiyama; Hisao Ogawa
Journal:  J Cardiol Cases       Date:  2011-11-27

Review 2.  Nesiritide: a review of its use in acute decompensated heart failure.

Authors:  Gillian M Keating; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Genetic variation in the natriuretic peptide system and heart failure.

Authors:  David E Lanfear
Journal:  Heart Fail Rev       Date:  2008-10-11       Impact factor: 4.214

Review 4.  Clinical applications of N-terminal pro B-type natriuretic peptide in heart failure and other cardiovascular diseases.

Authors:  Da-Rong Pu; Jun R Chiong; Qi-chang Zhou
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

5.  The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population.

Authors:  I Raymond; B A Groenning; P R Hildebrandt; J C Nilsson; M Baumann; J Trawinski; F Pedersen
Journal:  Heart       Date:  2003-07       Impact factor: 5.994

6.  N-Terminal Pro-B-type Natriuretic Peptide Levels in the Korean General Population.

Authors:  Kyung-Hoon Lee; Jang-Young Kim; Sang-Baek Koh; Seung-Hwan Lee; Junghan Yoon; Sang-Woo Han; Jong-Ku Park; Kyung-Hoon Choe; Byung-Su Yoo
Journal:  Korean Circ J       Date:  2010-12-31       Impact factor: 3.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.